AtriCure, Inc. logo

AtriCure, Inc. (ATRC)

Market Closed
1 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
48. 92
+0.57
+1.1789%
$
2.46B Market Cap
- P/E Ratio
- Div Yield
717,636 Volume
-0.76 Eps
$ 48.35
Previous Close
Add Transaction
Day Range
47.54 49.25
Year Range
25.36 49.98
Want to track ATRC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ATRC closed today higher at $48.92, an increase of 1.1789% from yesterday's close, completing a monthly increase of 26.2777% or $10.18. Over the past 12 months, ATRC stock gained 23.1932%.
ATRC is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0.113%. On average, the company has surpassed earnings expectations by 0.0843%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

ATRC Chart

People also search for

Applied Optoelectronics, Inc.
$ 103.39
-3.9929%
Appfolio Inc.
$ 225.28
-3.8128%
TTD
The Trade Desk, Inc. Class A
$ 13.78
+0.4373%
Camtek Ltd.
$ 128.14
-4.3731%
GDS
GDS Holdings Ltd. - ADR
$ 31.24
-1.9152%
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks | 5 days ago
AtriCure: Promising Cardiovascular Surgical Platform

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.

Seekingalpha | 1 week ago
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.

Marketbeat | 3 weeks ago

AtriCure, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Curtis Ellergodt
Curtis Ellergodt Rothschild Investment LLC
168 $5,066.92 $6,609.12 $1,542.2 30.44%
PER
Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc.
113,330 $4.29M $4.94M $643,965.32 15%
SN
Stephanie Nee HARBOR CAPITAL ADVISORS Inc.
42,385 $1.38M $1.75M $378,352.58 27.5%
BG
Bart Gancher Intech Investment Management LLC
10,584 $340,768.34 $438,071.76 $97,303.42 28.55%
JM
John Malone Amundi
264,854 $8.83M $11.38M $2.55M 28.88%

AtriCure, Inc. (ATRC) FAQ

What is the stock price today?

The current price is $48.92.

On which exchange is it traded?

AtriCure, Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is ATRC.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 2.46B.

Has AtriCure, Inc. ever had a stock split?

No, there has never been a stock split.

AtriCure, Inc. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Michael H. Carrel CEO
NASDAQ (NMS) Exchange
04963C209 CUSIP
US Country
1,350 Employees
- Last Dividend
- Last Split
5 Aug 2005 IPO Date

Overview

AtriCure, Inc. is a medical device company that specializes in the development, manufacturing, and sales of surgical tools designed for the ablation of cardiac tissue, the exclusion of the left atrial appendage, and the temporary blocking of pain through peripheral nerve ablation. The company operates on a global scale, with a significant presence in the United States, Europe, the Asia-Pacific region, and other international markets. Since its incorporation in 2000, AtriCure has established its headquarters in Mason, Ohio, and has expanded its market reach through a combination of direct sales staff and independent distributors. AtriCure's mission is centered around innovating cardiac care, particularly focusing on solutions to address atrial fibrillation and related conditions.

Products and Services

AtriCure boasts a diverse portfolio of products and services designed to support cardiac surgery and pain management. The company’s offerings include:

  • Isolator Synergy Clamps: These clamps are single-use, disposable products utilizing radio frequency to facilitate surgical ablation of cardiac tissue. They represent a cornerstone of AtriCure’s ablation solutions.
  • MAX Pen Device: A multifunctional pen that enables surgeons to diagnose cardiac arrhythmias, perform temporary cardiac pacing, sensing, stimulation, and ablate cardiac tissue using a single device. This innovative approach streamlines procedures by consolidating functionalities.
  • Coolrail Device: Designed to create longer linear lines of ablation, the Coolrail device simplifies the process of cardiac tissue ablation, making it more efficient for surgeons to perform complex procedures.
  • cryoICE Cryoablation System: This system allows for the creation of linear ablations of varying lengths through cryoablation, offering an alternative modality to treat cardiac arrhythmias.
  • EPi-Sense Systems: A cutting-edge solution for the treatment of persistent atrial fibrillation, the EPi-Sense System is a single-use device that represents AtriCure’s commitment to addressing complex cardiac conditions.
  • cryoSPHERE Probe: Specifically designed for pain management, the cryoSPHERE probe applies cryothermic energy to targeted peripheral nerves in the ribcage to provide temporary relief from pain.
  • AtriClip System: This system features an implantable device paired with a single-use disposable applier, intended for the exclusion of the left atrial appendage, a procedure often required in the management of atrial fibrillation.
  • LARIAT System: As a suture-based solution for soft-tissue closure, the LARIAT System exemplifies AtriCure’s innovative approach to post-procedural care, offering a novel method for securing tissue after surgical interventions.
  • Additional Tools: AtriCure also supplies a range of supplementary tools such as the Lumitip dissectors for tissue separation, Glidepath guides for clamp placement, Subtle Cannula’s to facilitate access for EPi-Sense catheters, and various reusable instruments for cardiac surgery, underlining the company’s comprehensive approach to cardiac care solutions.

Contact Information

Address: 7555 Innovation Way
Phone: 513 755 4100